Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/14/2012DE102010053748A1 Composition, useful to treat and/or prevent obesity, comprises a specified range of hydoxycarboxylic acid, protein powder, sodium bicarbonate and magnesium carbonate
06/14/2012CA2823837A1 Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
06/14/2012CA2823642A1 Subcutaneously infusible levodopa prodrug compositions and methods of infusion
06/14/2012CA2821109A1 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
06/14/2012CA2820984A1 A complex of garcinol, cyclodextrin and method thereof
06/14/2012CA2820884A1 Polycyclic lpa1 antagonist and uses thereof
06/14/2012CA2820883A1 Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products
06/14/2012CA2820838A1 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
06/14/2012CA2820835A1 New form of administration of enkephalinase inhibitor
06/14/2012CA2820818A1 Method of extracting active molecules from natural resins and use thereof
06/14/2012CA2820817A1 Lysophosphatidic acid receptor antagonists and uses thereof
06/14/2012CA2820800A1 Triazole derivatives as wnt signaling pathway inhibitors
06/14/2012CA2820790A1 Compositions and methods for nutrient delivery
06/14/2012CA2820782A1 Bispecific aptamers mediating tumour cell lysis
06/14/2012CA2820763A1 Multifunctional nitroxide derivatives and uses thereof
06/14/2012CA2820748A1 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
06/14/2012CA2820694A1 Carnosine - hyaluronic acid mixtures and their use
06/14/2012CA2820586A1 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
06/14/2012CA2820435A1 Glycomimetic compounds as anti-infectious against pathogens lectins
06/14/2012CA2820431A1 Dosage form
06/14/2012CA2820416A1 New pharmaceutical compositions
06/14/2012CA2820394A1 Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections
06/14/2012CA2820393A1 Process for the manufacture of ajoene derivatives
06/14/2012CA2820389A1 [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
06/14/2012CA2820362A1 Substituted pyrazolopyrimidines as glucocerebrosidase activators
06/14/2012CA2820297A1 Implantable devices coated with insulin-mimetic agent composites and methods thereof
06/14/2012CA2820262A1 Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
06/14/2012CA2820245A1 Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
06/14/2012CA2820124A1 Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
06/14/2012CA2820114A1 Compound for the treatment of tumours and tumour metastases
06/14/2012CA2820109A1 Pyridine amide derivatives as ep4 receptor antagonists
06/14/2012CA2820075A1 Imidazo [1, 2-a] pyridine sulfonamides as trpm8 modulators
06/14/2012CA2820065A1 Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012CA2820044A1 Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012CA2820035A1 Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012CA2819955A1 Substituted imidazoquinoline derivatives
06/14/2012CA2819951A1 Dosages of arylsulfonamide derivatives
06/14/2012CA2819889A1 Substituted pyridinone-pyridinyl compounds
06/14/2012CA2819859A1 Methods for treating baldness and promoting hair growth
06/14/2012CA2819824A1 Macrocyclic inhibitors of flaviviridae viruses
06/14/2012CA2819810A1 Granzyme b inhibitor compositions, methods and uses for promoting wound healing
06/14/2012CA2819595A1 Methods and compositions useful for promoting sleep in animals
06/14/2012CA2819548A1 Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
06/14/2012CA2819466A1 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and related compounds and their use in therapy
06/14/2012CA2819373A1 Bicyclic compounds as pim inhibitors
06/14/2012CA2819277A1 Novel triazole compounds iii
06/14/2012CA2819130A1 Compositions and methods for mobilizing stem cells
06/14/2012CA2819087A1 Carboxamide compounds and their use as calpain inhibitors v
06/14/2012CA2818941A1 Janus kinase 2 (jak2) inhibitor for the treatment of lupus
06/14/2012CA2818936A1 Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative
06/14/2012CA2818669A1 Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
06/14/2012CA2818277A1 Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury
06/14/2012CA2818251A1 Oral care compositions comprising a quinone and a further antimicrobial agent
06/14/2012CA2818028A1 Hydroxylated tricyclic compounds
06/14/2012CA2818018A1 Liposomal formulation of dalcetrapib
06/14/2012CA2818012A1 Oligosaccharide composition for treating acute respiratory tract infections
06/14/2012CA2818011A1 Oligosaccharide composition for treating skin diseases
06/14/2012CA2817205A1 Hydantoin derivatives useful as kv3 inhibitors
06/14/2012CA2817122A1 Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
06/14/2012CA2816829A1 Triazolopyridine compounds
06/14/2012CA2816406A1 Hydroxylated aminotriazole derivatives as alx receptor agonists
06/14/2012CA2816376A1 Oxazolyl-methylether derivatives as alx receptor agonists
06/13/2012EP2463376A2 Food and beverages for treating metabolic osteopathy
06/13/2012EP2463375A2 Food and beverages for treating abdominal discomfort
06/13/2012EP2463372A1 Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
06/13/2012EP2463292A1 Compound having neurite-outgrowing activity
06/13/2012EP2463290A1 Thienooxazepine derivative
06/13/2012EP2463289A1 Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
06/13/2012EP2463286A1 Benzyl piperidine compound
06/13/2012EP2463285A1 Co-crystals and pharmaceutical compositions comprising the same
06/13/2012EP2463284A1 Co-crystals and pharmaceutical compositions comprising the same
06/13/2012EP2463283A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
06/13/2012EP2463282A1 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
06/13/2012EP2463279A1 Amide derivative
06/13/2012EP2463278A1 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
06/13/2012EP2463276A1 Nitrogenous-ring acylguanidine derivative
06/13/2012EP2462991A1 Composition and use of a fermented olive leaf product for the treatment of nail infections
06/13/2012EP2462990A1 Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect
06/13/2012EP2462989A1 Use of compounds to induce axonal growth
06/13/2012EP2462959A1 Methods and products for treatment of diseases
06/13/2012EP2462958A2 Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
06/13/2012EP2462957A2 Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
06/13/2012EP2462951A1 Use of two microrna moleculars in lung cancer prognosis and medicine preparation
06/13/2012EP2462939A2 Bioabsorbable adhesive compounds and compositions
06/13/2012EP2462938A1 Anionic polymer, polyion complex using anionic polymer, ternary polymer composite, and pharmaceutical composition
06/13/2012EP2462937A1 Modulation of LMW-PTPase Expression
06/13/2012EP2462936A1 SiRNA mediated post-transriptional gene-silencing of genes involved in alopecia
06/13/2012EP2462935A1 Process for the preparation of tenofovir
06/13/2012EP2462934A1 Anti-tumor activity of temsirolimus in papillary renal cell cancer
06/13/2012EP2462933A1 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
06/13/2012EP2462932A1 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
06/13/2012EP2462930A1 Induction of an immune response against dengue virus using prime-boost approach
06/13/2012EP2462927A1 Transdermal therapeutic system comprising fentanyl
06/13/2012EP2462923A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
06/13/2012EP2462922A1 New form of administration of enkephalinase inhibitor
06/13/2012EP2462921A1 Liquid pharmaceutical compositions for the treatment of a posterior eye disease
06/13/2012EP2462435A2 Identification and use of compounds for treating persistent pain
06/13/2012EP2462229A2 Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
06/13/2012EP2462154A2 Novel crystal form of cdb-4124 and process for the preparation thereof
06/13/2012EP2462153A2 Bicyclic cyclohexose nucleic acid analogs
1 ... 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 ... 7860